A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.
- DOI
- 10.1136/rmdopen-2022-002359
- Published
- 2022 Sep
- Container
- RMD open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/rmdopen-2022-002359,
title = {A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.},
author = {Kastrati K and Aletaha D and Burmester GR and Chwala E and Dejaco C and Dougados M and McInnes IB and Ravelli A and Sattar N and Stamm TA and Takeuchi T and Trauner M and van der Heijde D and Voshaar MJH and Winthrop K and Smolen JS and Kerschbaumer A},
year = {2022},
journal = {RMD open},
doi = {10.1136/rmdopen-2022-002359},
url = {https://doi.org/10.1136/rmdopen-2022-002359}
}RIS
TY - JOUR TI - A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. AU - Kastrati K AU - Aletaha D AU - Burmester GR AU - Chwala E AU - Dejaco C AU - Dougados M AU - McInnes IB AU - Ravelli A AU - Sattar N AU - Stamm TA AU - Takeuchi T AU - Trauner M AU - van der Heijde D AU - Voshaar MJH AU - Winthrop K AU - Smolen JS AU - Kerschbaumer A PY - 2022 JO - RMD open DO - 10.1136/rmdopen-2022-002359 UR - https://doi.org/10.1136/rmdopen-2022-002359 ER -
APA
K, K., D, A., GR, B., E, C., C, D., M, D., IB, M., A, R., N, S., TA, S., T, T., M, T., D, V. D. H., MJH, V., K, W., JS, S., & A, K. (2022). A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.. RMD open. https://doi.org/10.1136/rmdopen-2022-002359
Source records
- pubmed · retrieved 2026-09-25T14:37:39.955Z